A5014834641- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Respiratory viral infections research
- Ear Surgery and Otitis Media
- Respiratory and Cough-Related Research
- Antibiotics Pharmacokinetics and Efficacy
- Streptococcal Infections and Treatments
- Emergency and Acute Care Studies
- Influenza Virus Research Studies
- Child and Adolescent Health
- Vaccine Coverage and Hesitancy
- Sinusitis and nasal conditions
- Antimicrobial Resistance in Staphylococcus
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical studies and practices
- Viral gastroenteritis research and epidemiology
- Immunodeficiency and Autoimmune Disorders
- Orthopedic Infections and Treatments
- Viral Infections and Vectors
- Cystic Fibrosis Research Advances
- COVID-19 Impact on Reproduction
- Cancer therapeutics and mechanisms
- Herpesvirus Infections and Treatments
- COVID-19 diagnosis using AI
- Viral Infections and Outbreaks Research
Pfizer (United States)
2005-2025
University of Minnesota System
2023
Global Vaccines (United States)
2023
Pfizer (China)
2017
Universidad de Ciencias Medicas
2005-2015
Universidad de San Jose
2011
Hospital Nacional de Niños
1992-2006
Advance (Japan)
2005
New York Proton Center
2005
InterScience (United States)
2003
We conducted a multicenter study of the safety, tolerability, and plasma pharmacokinetics parenteral formulation voriconazole in immunocompromised pediatric patients (2 to 11 years old). Single doses 3 or 4 mg/kg body weight were administered six five children, respectively. In multiple-dose study, 28 received loading 6 every 12 h on day 1, followed by 2 8. Standard population pharmacokinetic approaches generalized additive modeling used construct structural covariate models this analysis....
Abstract Background Healthcare workers are at increased risk of exposure to respiratory pathogens including Streptococcus pneumoniae (pneumococcus). While little asymptomatic carriage has been reported in young-to-middle-aged adults, this may be due nonsensitive diagnostic methods. The aim the current study was investigate rates pneumococcal a large cohort healthcare workers, using saliva as specimen. Methods We evaluated convenience samples saliva, self-collected from (Connecticut, USA) who...
Objectives. To determine the bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate (90/6.4 mg/kg/day) against common bacterial pathogens causing acute otitis media (AOM), including penicillin-resistant Streptococcus pneumoniae (PRSP). Methods. In this open label multicenter study, 521 infants children with AOM [mean age, 18.6 months; age <24 months, n = 375 (72%)] were treated 90/6.4 mg/kg/day in two divided doses for 10 days. Bilateral media, previous episodes AOM,...
We analyzed outpatient visits, incidence, antimicrobial prescriptions, and medical expenditures for acute otitis media (AOM) in the United States during 2011–2016. Data sources included National Disease Therapeutic Index (NDTI™) projections by IQVIA (for AOM cases), The Medical Expenditure Panel Survey expenditures) US Census population estimates). Analyses focused on children aged ≤9 years between 2011 2016. used 2014 expenditure estimate per episode ($520) as proxy all years. In 2011,...
The addition of pneumococcal conjugate vaccines (PCVs) to the United States (US) national immunization program led significant reductions in incidence, mortality, and associated sequelae caused by disease (PD) children adults through direct indirect protection. However, there remains clinical economic burden due PD serotypes not included current 13-valent PCV (PCV13) formulation. To address this unmet need, 15-valent (PCV15) 20-valent (PCV20), containing additional PCV13, were recently...
Reported rates of invasive pneumococcal disease were markedly lower than normal during the 2020/2021 winter in Northern Hemisphere, first year after start COVID-19 pandemic. However, little is known about carriage pneumococcus among adults this period. Between October 2020-August 2021, couples Greater New Haven Area, USA, enrolled if both individuals aged 60 years and above did not have any under age living household. Saliva samples questionnaires regarding social activities contacts medical...
As of June 2023, two pneumococcal conjugate vaccines, 20- (PCV20) and 15- (PCV15) valent formulations, are recommended for US infants under a 3 + 1 schedule. This study evaluated the health economic impact vaccinating with new expanded valency PCV20 formulation. A population-based, multi cohort, decision-analytic Markov model was developed to estimate public cost-effectiveness from both societal healthcare system perspectives over 10 years. Epidemiological data were based on published...
Penicillin-nonsusceptible Streptococcus pneumoniae isolates are confined mainly to a few serogroups. Capsular transformation may serve as mechanism for spreading antibiotic resistance new serotypes.Antibiogram and molecular typing, by pulsed-field gel electrophoresis (PFGE), were performed on 46 nasopharyngeal middle ear fluid (MEF) expressing serotype 11A, 45 MEF 15B/C (recovered during 1998-2003 from Israeli children <5 years old), 57 19F 1998-2001 Costa Rican <7.5 old).PFGE patterns...
Serial C-reactive protein (CRP) and erythrocyte sedimentation rate determinations were compared with clinical course outcome at 1 to 2 months in 63 children acute hematogenous osteomyelitis. High CRP values (163 \pm 108 mg/liter) on admission began descend after the second day of treatment. From fourth higher (P = 0.03 P 0.0001) distinguished a complicated from an uneventful osteomyelitis patients symptomatic follow-up 0.003 asymptomatic ones. Children who developed extensive radiographic...
Background: Fluoroquinolones, including levofloxacin, have not been recommended for use in children largely because studies juvenile laboratory animals suggest there may be an increased risk of fluoroquinolone-associated cartilage lesions. A large prospective trial is needed to assess the risks associated with using levofloxacin children. Objective: Assess safety and tolerability therapy based on observations 1 year after therapy. Methods: Safety data were collected who participated 3...
Background: Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) adults, its use as an alternative therapy for children with CAP been proposed. Objective: Assess clinical levofloxacin compared standard care antibiotic aged 6 months to 16 years. Methods: In open-label, multicenter, noninferiority trial, were randomized 3:1 receive or comparator antimicrobial (0.5 <5 years: amoxicillin/clavulanate ceftriaxone; ≥5 clarithromycin ceftriaxone...
Background. Trovafloxacin is a new fluoroquinolone that exhibits good penetration into the central nervous system and excellent antimicrobial activity against common meningeal pathogens, including beta-lactam-resistant pneumococci. Purpose design. A multicenter, randomized clinical trial was conducted in children with bacterial meningitis to compare safety efficacy of trovafloxacin ceftriaxone or without vancomycin therapy. Results. total 311 patients, ages 3 months 12 years, were enrolled,...